 |
|
serine protease inhibitor WX-671
An orally bioavailable, 3-amidinophenylalanine-derived, second generation serine protease inhibitor prodrug targeting the human urokinase plasminogen activator (uPA) system with potential antineoplastic and antimetastatic activities. After oral administration, serine protease inhibitor WX-671 is converted to the active Nα-(2,4,6-triisopropylphenylsulfonyl)-3-amidino-(L)-phenyla lanine-4-ethoxycarbonylpiperazide (WX-UK1), which inhibits several serine proteases, particularly uPA; inhibition of uPA may result in the inhibition of tumor growth and metastasis. uPA is a serine protease involved in degradation of the extracellular matrix and tumor cell migration and proliferation. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
| Code name: | | WX-671 | | | | Chemical structure name: | | N-α-(2,4,6-triisopropylphenyl-sulfonyl)-3-hydroxyamidino-(L )-phenylalanine-4-ethoxycarbonylpiperazide | | |
|
|
